The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy

Epilepsia

Volumn 40, Issue 10, 1999, Pages 1439-1445

  Wong, I C K ^a   Chadwick, D W ^b   Fenwick, P B C ^b   Mawer, G E ^b   Sander, J W A S ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b NONE

Author keywords

Chronic epilepsy; Gabapentin; Lamotrigine; Pharmacoepidemiology; Vigabatrin

Indexed keywords

GABAPENTIN; LAMOTRIGINE; VIGABATRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; DRUG USE; EPILEPSY; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HOSPITAL ADMISSION; HUMAN; INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ACETIC ACIDS; AMBULATORY CARE; AMINES; ANTICONVULSANTS; CHRONIC DISEASE; CLINICAL TRIALS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; EVIDENCE-BASED MEDICINE; GAMMA-AMINOBUTYRIC ACID; GREAT BRITAIN; HUMANS; LONGITUDINAL STUDIES; MEDICAL RECORDS; MULTICENTER STUDIES; PATIENT DROPOUTS; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZINES; VIGABATRIN;

EID: 0032841402     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02017.x     Document Type: Article

References (28)

1. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996; 313:1169-74.
2. Mignot G. Drug trials in epilepsy: new drugs have been poorly assessed. Br Med J 1996;313:1158-9.
3. Walker MC, Sander JWAS. Difficulties in extrapolating from clinical trial data to clinical practice: the case of anti-epilepetic drugs. Neurology 1997;49:333-7.
4. Brodie MJ. Commentry: antiepileptic drugs, clinical trials, and the marketplace. Lancet 1996;347:777-8.
5. Sander JWAS. New drugs for epilepsy. Curr Opin Neurol 1998; 11:141-8.
6. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-81.
7. Cox DR. Regression models and life tables. J R Statist Soc 1972; 34:187-202.
8. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO, 1996.
9. Office of Population Censuses and Surveys. Mortality statistics: general, review of the register general on deaths in England and Wales. Series DH1 no. 27. London: HMSO, 1992:6.
10. Sander JWAS, Sillanpaa M. Natural history and prognosis: In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:69-86.
11. Nashef L, Fish DR, Sander JWAS, Shorvon SD. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 1995;58:462-4.
12. Annegers JF, Coan SP, Hauser WA, Leestma J, Duffell W, Tarver B. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death. Epilepsia 1998;39: 206-12.
13. Makin AJ, Fitt S, Williams R, Duncan JS. Drug points: fulminant hepatic failure induced by lamotrigine. Br Med J 1995;311:292.
14. U.S. Gabapentin Study Group. Long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
15. Handforth A, Treiman DM. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994;35: 1032-7.
16. Ojemann LM, Wilensky AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992;13: 159-65.
17. Sivenius J, Ylinen A, Kalviainen R, Riekkinen PJ. Long-term study with gabapentin in patients with drug-resistant epileptic seizures. Arch Neurol 1994;51:1047-50.
18. Cocito L, Maffini M, Loeb C. Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res 1994;19:123-7.
19. Martin PJ, Millac PA. Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience. Seizure 1994;3:209-13.
20. Pisani F, Russo M, Trio R, Artesi C, Fazio A, Oteri G, Di-erri R. Lamotrigine in refractory epilepsy a long-term open study. Epilepsy Res 1991;(suppl 3): 187-91.
21. Sander JWAS, Trevisol-Bittencourt PC, Harl YM, Patsalos PN, Shorvon SD. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990;7:226-9.
22. Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990;5:240-6.
23. Buchanan N. Vigabatrin use in 72 patients with drug-resistant epilepsy. Seizure 1994;3:89-98.
24. Dam M. Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy. Epilepsia 1989;30:S26-30.
25. de-Bittencourt PRM, Mazer S, Marcourakis T, Bigarella MM, Ferreira ZS, Mumford JP. Vigabatrin: clinical evidence supporting rational polytherapy in management of uncontrolled seizures. Epilepsia 1994;35:373-80.
26. Martin PJ, Millac PA. Vigabatrin: a three year clinical analysis. Seizure 1993;2:137-40.
27. Pedersen SA, Klosterskov P, Gram L, Dam M. Long-term study of gamma-vinyl-GABA in patients with epilepsy. Acta Neurol Scand 1985;72:294-8.
28. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1008-10.